Research Article
S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms
Table 1
Overall population characteristics of patients with Type 2 Diabetes Mellitus (n=52).
| | Age (years) | 62 ± 12 |
| | Female | 35 (66. 7%) |
| | BMI (kg/m2) | 31.2 ± 5.6 |
| | Waist (cm) | 104 ± 22 |
| | Current smoking | 13 (25%) |
| | Stroke/TIA | 2 (3. 8%) |
| | CAD | 10 (19 2%) |
| | Arterial Hypertension | 35 (67. 3%) |
| | MAP (mmHg) | 96 ± 10 |
| | Duration of diabetes (months) | 90 (36-240) |
| | Creatinine (mg/dl) | 0.8 ± 0.1 |
| | MDRD | 74 (67-105) |
| | LDL (mg/dl) | 112 (77-123) |
| | HDL (mg/dl) | 47 ± 14 |
| | Triglycerides (mg/dl) | 135 (96-228) |
| | HbA1c (%) | 7.1 ± 1.1 |
| | TNFa (pg/ml) | 8.1 ± 2.4 |
| | S100-B (pg/ml) | 2.2 (1.9-12.3) |
| | Medication |
| | Insulin | 10 (19. 2%) |
| | Metformin | 36 (69. 2%) |
| | DPP4 inhibitors | 12 (23. 1%) |
| | Sulphonylureas | 14 (26. 9%) |
| | ACE/ARBs | 27 (51. 9%) |
| | b-blockers | 18 (34. 6%) |
| | Antiplatelet treatment | 17 (32. 7%) |
| | Statin treatment | 28 (53. 8%) |
| | Depressive symptoms | 22 (42. 3%) |
| | Hamilton (interview) rating scale score (17) | 5 (3-9) |
| | Zung self-assessment score | 44 ± 10 |
|
|
BMI: body mass index, TIA: transient ischemic attack, CAD: cardiovascular disease, MAP: mean arterial pressure (MAP = [(2 x diastolic)+systolic]/3, MDRD: GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) (mL/min/1.73 m2), LDL: low density lipoprotein, HDL: high density lipoprotein, HbA1c: glycated hemoglobin; TNFa: tumor necrosis factor a, S100B: S100 calcium binding peptide b; DPP4 inhibitors: dipeptidyl-peptidase 4 inhibitors; ACE: angiotensin-converting-enzyme inhibitor, and ARBs: angiotensin receptor blockers.
|
